[ad_1]
David Samadi, MD, urological oncologist, director of men’s health, St. Francis, Roslyn, NY.
Otis W. Brawley, MD, Bloomberg is a distinguished professor of oncology and epidemiology at Johns Hopkins University, Baltimore.
James Eastham, MD, Chief, Urology Service, Memorial Sloan Kettering Cancer Center, New York City.
Maurie Markman, MD, Medical Oncologist; president of medicine and science at the American Cancer Center.
National Comprehensive Network on Cancer: “NCCN Guidelines”.
Rachel Darwin, spokeswoman for the National Comprehensive Cancer Network.
American Urological Association: “Early Detection of Prostate Cancer”.
The New York Times: “Debate on the value of PSA prostate screening.”
Urology Times: “The Big ‘Scam of Prostate Cancer: A Call to Arms.”
Premiere Medical Group: “Dealing with Controversy – A PSA Question.”
American Society of Clinical Oncology: “Decision Assistance Tool: Screening for Prostate Cancer with PSA Testing.”
Research and Clinical Urology: “Prostate Cancer Screening.”
Oncotypeiq.com: “On the oncotype DX test of genomic evaluation of the prostate.”
JAMA Oncology: “Validation of the 22-gene genomic classifier in patients with recurrent prostate cancer: an ancillary study NRG / RTOG 9601 randomized clinical trial.”
CyberKnife.com: “Accurate, accurate and convenient solution for prostate cancer treatment.”
MDAnderson.org: “Proton Therapy for Prostate Cancer.”
Urology Today: “The Challenges of Prostate Cancer Management.”
American Cancer Society: “Tests to Diagnose and Stage Prostate Cancer,” “What’s New in Prostate Cancer Research.”
[ad_2]
Source link
